Table 1.
Demographic characteristics and disease-related characteristics.
| Characteristic / Type of regimen N (%) | ECF (n = 32) | DCF (n = 51) | FOLFOX (n = 37) | FLOT (n=32) | P-value |
|---|---|---|---|---|---|
| Age (years) | 55.73 ± 10.68 | 54.47 ± 10.38 | 60.11 ± 13.88 | 52.16 ± 12.24 | 0.03 |
| Sex | |||||
| Male | 20 (62.5%) | 39 (76.5%) | 27 (73%) | 20 (62.5%) | 0.41 |
| Female | 13 (37.5%) | 12 (23.5%) | 10 (27%) | 12 (37.5%) | |
| BMIa (kg/m2) | |||||
| < 18 | 7 (21.9%) | 9 (17.6%) | 12 (32.4%) | 5 (15.6%) | |
| 18-24 | 17 (53.1%) | 32 (62.8%) | 17 (45.9%) | 23 (71.9%) | 0.35 |
| > 24 | 8 (25%) | 10 (19.6%) | 8 (21.7%) | 4 (12.5%) | |
| ECOG performance statusb | |||||
| 0 | 12 (37.5%) | 29 (56.8%) | 21 (56.3%) | 16 (50%) | |
| 1 | 18 (56.2%) | 16 (31.4%) | 15 (40.5%) | 14 (43.7%) | 0.4 |
| 2 | 2 (6.3%) | 6 (11.8%) | 1 (2.7%) | 2 (6.3%) | |
| History of smoking | 19 (59.4%) | 37 (72.5%) | 15 (41.7%) | 9 (29.0%) | 0.001 |
| Family history of cancer | 13 (40.6%) | 11 (21.6%) | 9 (24.3%) | 7 (21.9%) | |
| History of H. pylori infection | 15 (46.9%) | 30 (58.5%) | 17 (45.9%) | 13 (40.6%) | |
| Pathology differentiation | |||||
| Well-differentiated | 12 (37.5%) | 23 (45.1%) | 21 (56.8%) | 16 (50%) | 0.41 |
| Poorly differentiated | 20 (62.5%) | 28 (54.9%) | 16 (43.2%) | 16 (50%) | |
| Tumor site | |||||
| Proximal | 16 (50%) | 26 (51%) | 25 (67.6%) | 19 (59.3%) | 0.63 |
| Distal | 14 (43.7%) | 22 (43.1%) | 11 (29.7%) | 10 (31.3%) | |
| Total involvement | 2 (6.3%) | 3 (5.9%) | 1 (2.7%) | 3 (9.4%) | |
| Tumor size | |||||
| < 4cm | 13 (40.6%) | 20 (39.2%) | 18 (48.6%) | 13 (41.9%) | 0.84 |
| > 4cm | 19 (59.4%) | 31 (60.8%) | 19 (51.4%) | 18 (58.1%) | |
| Depth of tumors’ invasion | |||||
| T1 | 1(3.1%) | 1 (2%) | 4 (10.8%) | 3 (9.4%) | |
| T2 | 8 (25%) | 16 (31.3%) | 12 (32.4%) | 13 (40.6%) | 0.28 |
| T3 | 18 (56.3%) | 20 (39.2%) | 17 (46%) | 11 (34.4%) | |
| T4 | 5 (15.6%) | 14 (27.5%) | 4 (10.8%) | 5 (15.6%) | |
| Lymph node metastasis | |||||
| N0 | 1 (3.1%) | 2 (3.9%) | 8 (21.6%) | 6 (18.7%) | |
| N1 | 16 (50%) | 21 (41.2%) | 17 (46%) | 15 (46.9%) | |
| N2 | 11 (31.5%) | 20 (39.2%) | 11 (29.7%) | 10 (31.3%) | 0.004 |
| N3 | 4 (12.5%) | 8 (15.7%) | 1 (2.7%) | 1 (3.1%) | |
| Metastasis c | |||||
| No metastasis | 29 (90.6%) | 38 (74.5%) | 35 (94.6%) | 28 (87.5%) | 0. 51 |
| Limited metastasis | 3 (9.4%) | 13 (25.5%) | 2 (5.4%) | 4 (12.5%) | |
| Site of metastasis | |||||
| Extra abdominal lymph node | 1 (3.1%) | 2 (3.9%) | 1 (2.7%) | 2 (6.5%) | |
| Liver | 1 (3.1%) | 11 (21.6%) | 1 (2.7%) | 2 (6.5%) | 0.42 |
| Stage based on TNM | |||||
| 1B | 0 (0%) | 2 (3.9%) | 8 (21.6%) | 7 (21.8%) | |
| 2A | 7 (21.8%) | 6 (11.7%) | 8 (21.6%) | 8 (25%) | |
| 2B | 6 (18.7%) | 11 (21.5%) | 4 (10.8%) | 6 (18.8%) | |
| 3A | 10 (31.3%) | 9 (17.6%) | 7 (19%) | 3 (9.4%) | 0.005 |
| 3B | 7 (21.9%) | 12 (23.5%) | 9 (24.3%) | 5 (15.6%) | |
| 4 | 2 (6.3%) | 11 (21.5%) | 1 (2.7%) | 3 (9.4%) | |
| Type of surgery | 0.50 | ||||
| Total gastrectomy | 29 (90.6%) | 43 (84.3%) | 34 (91.9%) | 30 (93.8%) | |
| Partial gastrectomy | 3 (9.4%) | 8 (15.7%) | 3 (8.1%) | 2 (6.2%) | |
| Tumors’ invasion | 0.53 | ||||
| Lymphatic invasion | 12 (37.5%) | 18 (35.3%) | 12 (32.4%) | 11 (35.5) | |
| Vascular invasion | 5 (15.6%) | 8 (15.7%) | 4 (10.8%) | 2 (6.5%) | |
| Peritoneal invasion | 1 (3.1%) | 1 (2.1%) | 0 (0%) | 1 (3.2%) | |
| Perineural | 3 (9.4%) | 11 (21.6%) | 2 (5.4%) | 4 (12.9%) | |
| Liver | 1 (3.1%) | 8 (15.7%) | 2 (5.4%) | 1 (3.2%) |
a Body mass index; b eastern cooperative oncology group; c metastases to the abdomen, retroperitoneum and lymph node metastases, unilateral or bilateral adrenal gland or kukernburg tumors, regardless of retroperitoneal lymph node metastases, no obvious involvement of peritoneum or pleura either clinically or symptomatic, no evidence of carcinomatous of peritoneum at the time of diagnosis, five or fewer liver metastases (if only liver had involvement with the tumor).